biostudies-literatureChow EJStand Up To CancerUS National Institutes of HealthNCI NIH HHSAmerican Association for Cancer Research1203-1210https://www.ebi.ac.uk/biostudies/studies/S-EPMC8106632biostudies-literatureUnknown62(5)With tyrosine kinase inhibitor (TKI) therapy, chronic myelogenous leukemia (CML) is now a chronic disease. CML patients treated with TKIs (<i>n</i> = 1200) were identified from the OptumLabs^® Data Warehouse (de-identified claims and electronic health records) between 2000 and 2016 and compared with a non-cancer cohort (<i>n</i> = 7635). The 5-year cumulative incidence of all organ system outcomes was significantly greater for the TKI versus non-cancer group. In the first year, compared with imatinib, later generation TKIs were associated with primary infections (hazard ratios [HR] 1.43, 95% CI 1.02-2.00), circulatory events (HR 1.15, 95% CI 1.01-1.31), and skin issues (HR 1.43, 95% CI 1.13-1.80); musculoskeletal and nervous system/sensory issues were less common (HRs 0.83-0.84, Leukemia & lymphomaAdverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.PMC8106632P30 CA015704Chennupati SMorin PELyman GHHenk HJDoody DRChow EJWinestone LEWilkes JJBecker LKfalseAdverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.With tyrosine kinase inhibitor (TKI) therapy, chronic myelogenous leukemia (CML) is now a chronic disease. CML patients treated with TKIs (<i>n</i> = 1200) were identified from the OptumLabs^® Data Warehouse (de-identified claims and electronic health records) between 2000 and 2016 and compared with a non-cancer cohort (<i>n</i> = 7635). The 5-year cumulative incidence of all organ system outcomes was significantly greater for the TKI versus non-cancer group. In the first year, compared with imatinib, later generation TKIs were associated with primary infections (hazard ratios [HR] 1.43, 95% CI 1.02-2.00), circulatory events (HR 1.15, 95% CI 1.01-1.31), and skin issues (HR 1.43, 95% CI 1.13-1.80); musculoskeletal and nervous system/sensory issues were less common (HRs 0.83-0.84, 2021-01-01T00:00:00Z2021 May2025-04-04T10:16:48.286Z2025-04-04T10:16:48.286ZS-EPMC81066323328355510.1080/10428194.2020.1855340